Genesis Biopharma partners with Lonza for Contego to treat metastatic melanoma

Genesis Biopharma, Inc. (OTC.BB:GNBP), a biotechnology company developing targeted cancer therapies, and Lonza (SIX: LONN), today announced the signing of a process development and scale-up agreement relating to the manufacture of Contego™, Genesis Biopharma's autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma.

Contego™ is a ready-to-infuse cell therapy based on currently available therapies at the National Cancer Institute, MD Anderson Cancer Center, and the H. Lee Moffitt Cancer & Research Institute.  "We are pleased to have such an experienced bioprocess development and manufacturing partner as Lonza," stated Mr. Anthony J. Cataldo, Chairman and Chief Executive Officer of Genesis Biopharma.  

"Lonza is pleased to be in partnership with Genesis Biopharma, and to bring expertise in large-scale autologous cell therapy production to the task of making Contego™ widely available to patients suffering from metastatic melanoma," said David Smith, Head of Therapeutic Cell Solutions at Lonza.

SOURCE Genesis Biopharma, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Melanoma incidence and mortality may eventually decrease among the entire Swedish population